Review
Cell Biology
Tanzeel Khan, Rashid Waseem, Mohammad Shahid, Jaoud Ansari, Ishfaq Ahmad Ahanger, Imtaiyaz Hassan, Asimul Islam
Summary: Alzheimer's disease is the most prevalent form of dementia, and there is currently no permanent cure. Stem cell therapy has shown promising results in preclinical studies and is being explored as a potential treatment. This article reviews research from the past decade, discusses hypotheses related to the pathology of Alzheimer's disease, and provides an overview of ongoing clinical trials for immunotherapy and stem cell therapy.
AGEING RESEARCH REVIEWS
(2023)
Review
Biochemistry & Molecular Biology
Atamjit Singh, Karanvir Singh, Jashandeep Kaur, Ramanpreet Kaur, Aman Sharma, Jasleen Kaur, Uttam Kaur, Renu Chadha, Preet Mohinder Singh Bedi
Summary: Alzheimer's disease, the most prevalent form of dementia worldwide, currently lacks effective treatment options. This review focuses on the pathogenesis of the disease and the development of 1,2,3-triazole containing derivatives as potential anti-Alzheimer's agents. The review provides insight into established targets of the disease and discusses the design, structure-activity relationships, and pharmacological outcomes of multifunctional anti-Alzheimer's agents containing 1,2,3-triazole. It serves as a baseline for future research groups working on Alzheimer's drug development.
ACS CHEMICAL NEUROSCIENCE
(2023)
Review
Biochemistry & Molecular Biology
Olga Krasnovskaya, Aina Kononova, Alexander Erofeev, Peter Gorelkin, Alexander Majouga, Elena Beloglazkina
Summary: There are over 55 million people with dementia worldwide and nearly 10 million new cases every year. Alzheimer's disease is the most common neurodegenerative disease that causes personality changes, cognitive impairment, memory loss, and physical disability. Early detection methods are important for early treatment of the disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Jasvinder Singh Bhatti, Satinder Kaur, Jayapriya Mishra, Harikrishnareddy Dibbanti, Arti Singh, Arubala P. Reddy, Gurjit Kaur Bhatti, P. Hemachandra Reddy
Summary: Alzheimer's disease (AD) is a neurodegenerative disease that involves synaptic damage, mitochondrial abnormalities, microRNA deregulation, hormonal imbalance, increased astrocytes & microglia, and accumulation of amyloid & beta; and phosphorylated Tau. Targeting mitochondrial proteins, including dynamin-related protein 1 (Drp1), may be a potential therapeutic approach for preventing AD pathology.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2023)
Review
Biochemistry & Molecular Biology
Ziyad M. Althafar
Summary: This study summarizes the molecular pathogenesis of Alzheimer's disease (AD), the activities of microglia in the adult brain, the role of microglia in the aging brain, and the significance of targeting microglia for the treatment of AD.
Review
Chemistry, Medicinal
Weimin Qiu, Hui Liu, Yijun Liu, Xin Lu, Lei Wang, Yanyu Hu, Feng Feng, Qi Li, Haopeng Sun
Summary: Alzheimer's disease (AD) is a difficult to treat progressive neurodegenerative disease characterized by the accumulation of amyloid beta (A beta) plaques in the brain. A beta interacts with various receptors on the plasma membrane and mediates signaling pathways that contribute to the development of AD. Despite ongoing research, there are currently no effective medications for AD. This review discusses the importance of A beta in the pathogenesis of AD, recent progress in targeting A beta-related receptors and compounds, and the challenges and opportunities in developing effective therapies for AD.
MEDICINAL RESEARCH REVIEWS
(2023)
Article
Biology
Ankita Srivastava, Maryann Johnson, Heather A. Renna, Katie M. Sheehan, Saba Ahmed, Thomas Palaia, Aaron Pinkhasov, Irving H. Gomolin, Joshua De Leon, Allison B. Reiss
Summary: P110, a peptide that inhibits mitochondrial fission, has shown neuroprotective effects in Alzheimer's disease by maintaining mitochondrial function and attenuating amyloid-beta generation. Cell culture studies revealed that P110 increased the expression of genes related to AD, while reducing the protein levels of APP and BACE1.
Review
Cell Biology
Mohammad Rafi Khezri, Mehdi Mohebalizadeh, Morteza Ghasemnejad-Berenji
Summary: Alzheimer's disease (AD) is the most common neurodegenerative disease worldwide, characterized by neuronal and synaptic loss in the central nervous system. The major causes of neuronal death in AD include accumulation of extracellular amyloid beta (Aβ) and aggregated tau proteins. Targeting the process of Aβ production to reduce its deposition has emerged as a potential therapeutic option for AD management. This review focuses on ADAM10, a protein involved in the non-amyloidogenic pathway of amyloid precursor protein processing, and discusses its molecular properties, role in AD, and potential as a therapeutic target to slow down disease progression.
CELL COMMUNICATION AND SIGNALING
(2023)
Review
Immunology
Nobufumi Sekino, Magdy Selim, Amjad Shehadah
Summary: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. It induces cerebral dysfunction, disruption of the blood-brain barrier, neuroinflammation, hypoperfusion, and accumulation of amyloid beta and tau protein in the brain. However, there is currently no specific treatment for cognitive impairments in sepsis. Antibiotics, targeting proinflammatory cytokines, and preventing ischemic injuries and hypoperfusion are suggested for the acute phase, while targeting neuroinflammation, blood-brain barrier dysfunction, protein phosphorylation, and specific receptors are suggested for the late phase of sepsis.
JOURNAL OF NEUROINFLAMMATION
(2022)
Review
Pharmacology & Pharmacy
Bruno P. Imbimbo, Stefania Ippati, Mark Watling, Camillo Imbimbo
Summary: According to the beta-amyloid (A beta) hypothesis, brain A beta accumulation is the primary cause of cognitive deficit and dementia in Alzheimer's disease (AD). While many anti-A beta drugs have failed in clinical trials, recent studies have shown encouraging results for antibodies that clear amyloid plaques. These findings suggest that decreased levels of soluble monomeric A beta may be the main driver of AD, rather than the aggregated forms.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Medicine, Research & Experimental
Sagheer Ahmed, Sidrah Tariq Khan, Muhammad Kazim Zargaham, Arif Ullah Khan, Saeed Khan, Abrar Hussain, Jalal Uddin, Ajmal Khan, Ahmed Al-Harrasi
Summary: Alzheimer's disease is the most common type of dementia affecting the later years of life and will be a major burden on the healthcare system. Despite scientific advancements, there are still no therapies available to stop or slow the progression of the disease. FDA has approved certain drugs for AD treatment, but research also suggests potential benefits from herbal compounds.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Cell Biology
Rahat Ullah, Tae Ju Park, Xu Huang, Myeong Ok Kim
Summary: Alzheimer's disease is an incurable neurodegenerative disorder associated with aging, and the accurate diagnosis and treatment of it is a challenging task. Research has shown that the abnormal interaction between central brain and peripheral A beta peptide metabolism plays a key role in the development of AD.
AGEING RESEARCH REVIEWS
(2021)
Article
Biochemistry & Molecular Biology
Priyanka Nagu, Vivek Sharma, Tapan Behl, Amjad Khan A. Pathan, Vineet Mehta
Summary: Wnt signaling is essential for neurogenesis and plays a crucial role in the development and differentiation of neurons in the adult brain. Impaired Wnt signaling pathways are directly associated with the pathogenesis of Alzheimer's disorder (AD). Activation of Wnt signaling improves cognitive functions and restores neurogenesis in animal models. Various natural and synthetic molecules have been identified to modulate Wnt signaling and promote neurogenesis, which could be beneficial in managing AD. However, more research is needed on the role of Wnt signaling in AD patients to further understand the pathogenesis and identify novel therapeutic targets.
JOURNAL OF MOLECULAR NEUROSCIENCE
(2022)
Review
Biochemistry & Molecular Biology
Anne-Cathrine S. Vogt, Gary T. Jennings, Mona O. Mohsen, Monique Vogel, Martin F. Bachmann
Summary: Alzheimer's disease is the most common form of dementia and is responsible for 60-70% of cases. The number of people with dementia is expected to triple by 2050 due to an aging population. Currently, there are only symptomatic treatments available, making it crucial to develop novel therapeutic strategies to prevent or delay the onset of Alzheimer's disease. This mini-review focuses on the understanding of Alzheimer's disease pathobiology and discusses current immunomodulating therapies targeting amyloid-beta protein.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Neurosciences
Nazhakaiti Palihati, Yuanhong Tang, Yajuan Yin, Ding Yu, Gang Liu, Zhenzhen Quan, Junjun Ni, Yan Yan, Hong Qing
Summary: In recent years, the glycosylated protein Clusterin has attracted extensive research attention, especially in Alzheimer's disease. It is closely associated with the occurrence and progression of AD and may affect the pathogenesis through mechanisms such as regulating inflammation, controlling cell apoptosis, and clearing pathological proteins. Further research on the relationship between Clusterin and AD is essential for a deeper understanding of the etiology and developing early diagnostic and therapeutic strategies.
MOLECULAR NEUROBIOLOGY
(2023)
